The collaboration combines Hobré’s analytics expertise with Fike’s proven safety solutions.
The FDA’s “no questions” letter means the agency has reviewed Onego Bio’s safety dossier and found no reason to challenge its conclusion that the product is safe for consumption.
The purchase agreement, announced Sept. 22, is subject to customary closing conditions.
The OLESSENCE™ line is designed to meet the rising consumer demand for fresh foods made with natural, label-friendly ingredients.
Biotechnology solutions present a new horizon of innovation and opportunity for global food, beverage and pharmaceutical markets.